Protocol Ledger

NCT07195227 · Phase II · RECRUITING

Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

Interventional Phase II clinical trial protocol NCT07195227 sponsored by MedSIR in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-24 Enrollment: 150 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07195227
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07195227
Protocol FieldVerified Registry Value
NCT IdentifierNCT07195227
Consolidated Lead SponsorMedSIR
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment150 participants (ESTIMATED)
Registered Start Date2026-03-24
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI